The next step in cardiovascular protection

Atherosclerosis Supplements

Volumn 4, Issue 5, 2003, Pages 3-9

  Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute coronary syndrome; Clinical equivalence; Inflammation; Lipids; Pravastatin; PROVE IT

Indexed keywords

ABCIXIMAB; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ATORVASTATIN; AZITHROMYCIN; BIVALRUDIN; GATIFLOXACIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SARUPLASE; SIMVASTATIN; STREPTOKINASE; THROMBIN INHIBITOR; TIROFIBAN; UNCLASSIFIED DRUG; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ANTIBIOTIC THERAPY; ATHEROSCLEROTIC PLAQUE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; INFECTION; INFLAMMATION; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; BLOOD; RECURRENT DISEASE;

ANGINA, UNSTABLE; ANTI-BACTERIAL AGENTS; ANTICHOLESTEREMIC AGENTS; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CHOLESTEROL, LDL; CLINICAL TRIALS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; PRAVASTATIN; PYRROLES; RECURRENCE;

EID: 1442302947     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(03)90001-8     Document Type: Article

References (25)

1. American Heart Association. 2000 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 1999.
2. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Clinical Practice Guideline Number 10 (amended). Agency for Health Care Policy and Research (AHCPR), 1994.
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40(7):1366-74.
4. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Study (4S). Lancet 1994;344(8934):1383-9.
5. Sacks M, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Trial investigators. N Engl J Med 1996;335(14):1001-9.
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 1998;339(19):1349-57.
7. Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection study: preliminary results. Int J Clin Pract 2002;56(1):53-6.
8. Cannon CP, McCabe CH, Belder R, et al. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT)-TMI 22 trial. Am J Cardiol 2002;89(7):860-1.
9. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360(9346):1623-30.
10. Arntz HR, Agrawal R, Wunderlic W, et al. Beneficial effects of pravastatin (+/- colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] study). Am J Cardiol 2000;86(12):1293-8.
11. Liem AH, van Boven AJ, Veeger NJ, et al. Effect of fluvastatin on ischemia following acute myocardial infarction: a randomized trial. Eur Heart J 2002;23(24):1931-7.
12. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285(13):1711-8.
13. Blazing MA, De Lemos JA, Dyke CK, et al. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001;142(2):211-7.
14. Tebbe U, Michels R, Adgey J, et al. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMPASS) Investigators. J Am Coll Cardiol 1998;31(3):487-93.
15. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289(7):853-63.
16. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Assessment of the safety and efficacy of a new thrombolytic investigators. Lancet 1999;354(9180):716-22.
17. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Eng J Med 2002;347(20):1557-65.
18. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2(8618):983-6.
19. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350(9075):430-6.
20. Cercek B, Shah PK, Noc M, et al. Effect of short-term treatment with azithromycin on recurrent ischemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomized controlled trial. Lancet 2003;361(9360):809-13.
21. Stone AF, Mendall MA, Kaski JC, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002;106(10):1219-23.
22. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999;99(12):1540-7.
23. Dunne MW. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD trial. J Infect Dis 2000;181(S3):572-8.
24. Coletta A, Thakeray S, Nikitin N, et al. Clinical trials update:highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP 2-trial and HARDBALL, Eur J Heart Failure 2002;4:381-8.
25. Jackson LA. Description and status of the Azithromycin and Coronary Events Study (ACES). J Infect Dis 2000;181(S3):579-81.